ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND

被引：3
|
作者：
Bozzarelli, S. [1 ]
Rimassa, L. [1 ]
Giordano, L. [1 ]
Garassino, I. [1 ]
Marrari, A. [1 ]
Tronconi, M. C. [1 ]
De Sanctis, R. M. [1 ]
Cavina, R. [1 ]
Baretti, M. [1 ]
Personeni, N. [1 ]
Pressiani, T. [1 ]
Santoro, A. [1 ]
机构：
[1] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Rozzano, MI, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv348.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
R59
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [41] Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
    Bruix, Jordi
    Tak, Won-Young
    Gasbarrini, Antonio
    Santoro, Armando
    Colombo, Massimo
    Lim, Ho-Yeong
    Mazzaferro, Vincenzo
    Wiest, Reiner
    Reig, Maria
    Wagner, Andrea
    Bolondi, Luigi
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (16) : 3412 - 3419
  • [42] A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing reimens
    Blackwell, Kimberly
    Kaplan, Edward H.
    Franco, Sandra X.
    Marcom, P. Kelly
    Maleski, Janet
    Sorensen, Mel
    Berger, Mark S.
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
  • [43] Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
    Emily Chan
    Eunice L. Kwak
    Jimmy Hwang
    Marja Heiskala
    Guillaume de La Bourdonnaye
    Monica Mita
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 701 - 709
  • [44] Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
    Chan, Emily
    Kwak, Eunice L.
    Hwang, Jimmy
    Heiskala, Marja
    de La Bourdonnaye, Guillaume
    Mita, Monica
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 701 - 709
  • [45] HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
    Besse, B.
    Awad, M.
    Forde, P.
    Thomas, M.
    Park, K.
    Goss, G.
    Rizvi, N.
    Huemer, F.
    Hochmair, M.
    Bennouna, J.
    Cosaert, J.
    Szucs, Z.
    Mortimer, P.
    Hobson, R.
    Sachsenmeier, K.
    Dean, E.
    Ambrose, H.
    Hayward, C.
    Dressman, M.
    Barry, S.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S118 - S119
  • [46] Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
    Weber, Jeffrey
    Gibney, Geoffrey
    Kudchadkar, Ragini
    Yu, Bin
    Cheng, Pingyan
    Martinez, Alberto J.
    Kroeger, Jodie
    Richards, Allison
    McCormick, Lori
    Moberg, Valerie
    Cronin, Heather
    Zhao, Xiuhua
    Schell, Michael
    Chen, Yian Ann
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (04) : 345 - 353
  • [47] Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
    Kim, Ju Won
    Lee, Hyo Jin
    Lee, Ji Yoon
    Park, Sook Ryun
    Kim, Yu Jung
    Hwang, In Gyu
    Kyun Bae, Woo
    Byun, Jae Ho
    Kim, Jung Sun
    Kang, Eun Joo
    Lee, Jeeyun
    Shin, Sang Joon
    Chang, Won Jin
    Kim, Eun-Ok
    Sa, Jason K.
    Park, Kyong Hwa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [48] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael Sangmin
    Wolf, Ido
    Fakih, Marwan
    De Vos-Geelen, Judith De
    Lee, Valerie
    Vogel, Arndt
    Wu, Larry
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
    Christina M. Annunziata
    Elise C. Kohn
    Patricia LoRusso
    Nicole D. Houston
    Robert L. Coleman
    Manuela Buzoianu
    Gabriel Robbie
    Robert Lechleider
    Investigational New Drugs, 2013, 31 : 77 - 84
  • [50] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
    Annunziata, Christina M.
    Kohn, Elise C.
    LoRusso, Patricia
    Houston, Nicole D.
    Coleman, Robert L.
    Buzoianu, Manuela
    Robbie, Gabriel
    Lechleider, Robert
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 77 - 84
12345